{"id":602,"date":"2026-02-28T13:09:42","date_gmt":"2026-02-28T13:09:42","guid":{"rendered":"https:\/\/heartcareforyou.in\/blog\/myocardial-hibernation-definition-clinical-context-and-cardiology-overview\/"},"modified":"2026-02-28T13:09:42","modified_gmt":"2026-02-28T13:09:42","slug":"myocardial-hibernation-definition-clinical-context-and-cardiology-overview","status":"publish","type":"post","link":"https:\/\/heartcareforyou.in\/blog\/myocardial-hibernation-definition-clinical-context-and-cardiology-overview\/","title":{"rendered":"Myocardial Hibernation: Definition, Clinical Context, and Cardiology Overview"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">Myocardial Hibernation Introduction (What it is)<\/h2>\n\n\n\n<p>Myocardial Hibernation is a condition in which heart muscle is alive but contracts weakly because it receives chronically reduced blood flow.<br\/>\nIt is a concept within ischemic heart disease and heart failure (HF) evaluation, not a symptom by itself.<br\/>\nIt is commonly encountered when assessing left ventricular (LV) dysfunction in coronary artery disease (CAD).<br\/>\nIt matters because some dysfunction may improve if blood flow is restored.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Why Myocardial Hibernation matters in cardiology (Clinical relevance)<\/h2>\n\n\n\n<p>Myocardial Hibernation sits at the intersection of anatomy (coronary blood supply), physiology (oxygen delivery and energy use), and clinical decision-making (medical therapy vs revascularization). The central clinical idea is \u201cviability\u201d: whether dysfunctional myocardium is still living and capable of functional recovery if perfusion improves.<\/p>\n\n\n\n<p>This concept is relevant for several reasons:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Diagnostic clarity in LV dysfunction:<\/strong> Patients with reduced ejection fraction (EF) may have ischemic cardiomyopathy, non-ischemic cardiomyopathy, mixed etiologies, or prior infarction with scar. Myocardial Hibernation helps explain why a region is weak without being permanently dead.<\/li>\n<li><strong>Treatment planning:<\/strong> Determining whether dysfunctional segments are viable can inform discussions about revascularization (percutaneous coronary intervention, PCI, or coronary artery bypass grafting, CABG) versus continued medical therapy. The approach varies by clinician and case.<\/li>\n<li><strong>Risk stratification:<\/strong> Extensive CAD with LV dysfunction is associated with higher risks of HF progression, arrhythmias, and adverse cardiovascular events. Identifying viable but jeopardized myocardium can refine clinical thinking about ischemic burden and potential reversibility.<\/li>\n<li><strong>Education and bedside reasoning:<\/strong> Myocardial Hibernation is a classic board-and-ward topic because it contrasts with myocardial infarction (irreversible necrosis) and myocardial stunning (transient dysfunction after acute ischemia with restored flow).<\/li>\n<\/ul>\n\n\n\n<p>Importantly, while viability assessment can guide decisions, the relationship between \u201cviability on imaging,\u201d improvement in LV function, and long-term outcomes is complex and can vary by patient factors, comorbidities, coronary anatomy, and protocol.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Classification \/ types \/ variants<\/h2>\n\n\n\n<p>Myocardial Hibernation is not typically classified into rigid \u201ctypes\u201d the way some diseases are. Instead, it is usually discussed along related categories that help clinicians communicate:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Acute vs chronic ischemic dysfunction (contextual classification):<\/strong><\/li>\n<li><em>Myocardial stunning<\/em> refers to transient post-ischemic dysfunction after blood flow is restored.<\/li>\n<li><em>Myocardial hibernation<\/em> refers to persistent dysfunction associated with chronically reduced perfusion or repetitive ischemia, with potential for improvement after revascularization.<\/li>\n<li><strong>Viable dysfunction vs non-viable scar (functional classification):<\/strong><\/li>\n<li><em>Viable myocardium<\/em> includes hibernating segments that are dysfunctional yet metabolically active.<\/li>\n<li><em>Non-viable myocardium<\/em> generally refers to scarred tissue after infarction with limited capacity to regain contractility.<\/li>\n<li><strong>Segmental vs global involvement (anatomic pattern):<\/strong><\/li>\n<li><em>Segmental hibernation<\/em> aligns with a coronary territory (e.g., left anterior descending artery distribution).<\/li>\n<li><em>More diffuse dysfunction<\/em> can occur in multivessel disease, sometimes making it harder to identify a single culprit territory.<\/li>\n<li><strong>Severity along a continuum (practical framing):<\/strong><\/li>\n<li>Some regions show mild hypokinesis with preserved thickness.<\/li>\n<li>Others show severe hypokinesis or akinesis but retain features of viability on imaging.<\/li>\n<\/ul>\n\n\n\n<p>These framings are used because Myocardial Hibernation is a physiologic state rather than a single anatomic lesion.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Relevant anatomy &amp; physiology<\/h2>\n\n\n\n<p>Understanding Myocardial Hibernation starts with coronary anatomy and myocardial energy physiology.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>\n<p><strong>Coronary circulation and territories:<\/strong><br\/>\n  The epicardial coronary arteries (left main, left anterior descending, left circumflex, right coronary artery) supply blood to the myocardium through branching arterioles and capillaries. Flow to each LV region often corresponds to a coronary territory, though overlap and dominance patterns vary.<\/p>\n<\/li>\n<li>\n<p><strong>Myocardial oxygen supply\u2013demand balance:<\/strong><br\/>\n  The heart extracts a high proportion of oxygen at baseline, so increased demand (heart rate, wall stress, contractility) is met primarily by increasing coronary blood flow. When flow is chronically limited by CAD, the myocardium may downregulate function to reduce demand.<\/p>\n<\/li>\n<li>\n<p><strong>Left ventricular function and wall stress:<\/strong><br\/>\n  LV systolic performance depends on synchronized contraction of viable muscle fibers and adequate perfusion. Chronic hypoperfusion can lead to regional wall motion abnormalities (hypokinesis\/akinesis) that reduce overall EF.<\/p>\n<\/li>\n<li>\n<p><strong>Microcirculation and endothelial function:<\/strong><br\/>\n  Beyond epicardial stenosis, microvascular dysfunction and impaired vasodilatory reserve can contribute to reduced perfusion, especially during stress. This can influence imaging results and clinical interpretation.<\/p>\n<\/li>\n<li>\n<p><strong>Remodeling and neurohormonal activation:<\/strong><br\/>\n  Chronic LV dysfunction triggers remodeling (changes in size, shape, fibrosis) and activation of systems such as the renin\u2013angiotensin\u2013aldosterone system (RAAS) and sympathetic nervous system, which can perpetuate HF even if some myocardium is viable.<\/p>\n<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Pathophysiology or mechanism<\/h2>\n\n\n\n<p>Myocardial Hibernation describes <strong>chronic reversible contractile dysfunction<\/strong> in viable myocardium associated with reduced perfusion and\/or repeated ischemia.<\/p>\n\n\n\n<p>Key mechanistic themes include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>\n<p><strong>Adaptive downregulation of contractility:<\/strong><br\/>\n  When oxygen delivery is persistently limited, myocardial cells may reduce contractile work to better match supply. This can be viewed as a survival strategy that preserves cell integrity at the cost of pump function.<\/p>\n<\/li>\n<li>\n<p><strong>Metabolic and cellular changes:<\/strong><br\/>\n  Hibernating myocardium tends to show shifts in energy utilization, alterations in calcium handling, and changes in gene expression associated with a \u201cfetal-like\u201d phenotype. Over time, there may be varying degrees of interstitial fibrosis, which can limit the degree of recovery.<\/p>\n<\/li>\n<li>\n<p><strong>Perfusion\u2013function mismatch:<\/strong><br\/>\n  A classic teaching point is that function is reduced \u201cmore than expected\u201d for resting perfusion, reflecting altered contractile machinery and chronic adaptation. In practice, this mismatch is assessed indirectly via imaging patterns rather than measured directly.<\/p>\n<\/li>\n<li>\n<p><strong>Difference from infarction and stunning:<\/strong> <\/p>\n<\/li>\n<li>In <strong>myocardial infarction<\/strong>, sustained ischemia causes myocyte death and replacement fibrosis; recovery of contraction in that scarred area is limited.  <\/li>\n<li>In <strong>stunning<\/strong>, a short ischemic episode followed by reperfusion produces temporary dysfunction that tends to improve with time, even without revascularization.  <\/li>\n<li>In <strong>hibernation<\/strong>, dysfunction persists until perfusion is improved and\/or the ischemic substrate is addressed; the timeline and degree of improvement vary by protocol and patient factors.<\/li>\n<\/ul>\n\n\n\n<p>Overall, the mechanism is not a single switch but a spectrum of viability, injury, and remodeling.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Clinical presentation or indications<\/h2>\n\n\n\n<p>Myocardial Hibernation is usually suspected rather than \u201cfelt.\u201d Typical clinical scenarios include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Reduced LV ejection fraction discovered on echocardiography in a patient with known or suspected CAD<\/li>\n<li>Chronic HF symptoms (e.g., exertional dyspnea, fatigue, reduced exercise tolerance) in the setting of ischemic risk factors<\/li>\n<li>Regional wall motion abnormalities on imaging that do not clearly match a completed infarction<\/li>\n<li>History of angina (or anginal equivalents) with LV dysfunction<\/li>\n<li>Multivessel CAD where clinicians are considering whether revascularization might improve function or symptoms<\/li>\n<li>Pre-procedural evaluation in selected patients before CABG or complex PCI, when viability information could influence planning (varies by clinician and case)<\/li>\n<li>Discordant findings such as severe dysfunction with relatively preserved wall thickness, raising suspicion for viability<\/li>\n<\/ul>\n\n\n\n<p>Because Myocardial Hibernation is a physiologic state, the \u201cindication\u201d is typically the need to evaluate viability and ischemic contributors to LV dysfunction.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Diagnostic evaluation &amp; interpretation<\/h2>\n\n\n\n<p>Evaluation aims to answer two linked questions:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Is there significant CAD that could limit perfusion?<\/strong> <\/li>\n<li><strong>Is the dysfunctional myocardium viable (hibernating) or predominantly scar?<\/strong><\/li>\n<\/ol>\n\n\n\n<p>Common components of the workup include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>\n<p><strong>History and physical examination:<\/strong><br\/>\n  Clinicians look for symptoms of HF and ischemia, prior myocardial infarction, revascularization history, and comorbidities (diabetes, chronic kidney disease, hypertension). Physical findings may reflect congestion or low output but are not specific for hibernation.<\/p>\n<\/li>\n<li>\n<p><strong>Electrocardiogram (ECG):<\/strong><br\/>\n  Prior Q waves, conduction abnormalities, or ischemic changes can support CAD history, but ECG cannot reliably distinguish hibernation from scar in all cases.<\/p>\n<\/li>\n<li>\n<p><strong>Laboratory testing:<\/strong><br\/>\n  Labs often assess HF severity and contributors (renal function, anemia, thyroid disease). Biomarkers can support HF diagnosis but do not diagnose Myocardial Hibernation.<\/p>\n<\/li>\n<li>\n<p><strong>Transthoracic echocardiography (TTE):<\/strong><br\/>\n  Echo is foundational for EF, LV size, regional wall motion, and valve disease. Preserved wall thickness in a severely dysfunctional segment can raise suspicion for viability, but echo alone may be insufficient.<\/p>\n<\/li>\n<li>\n<p><strong>Stress echocardiography with dobutamine (Dobutamine Stress Echo):<\/strong><br\/>\n  This is a classic viability test. Low-dose dobutamine may show <strong>contractile reserve<\/strong> (improved thickening), which supports viability. Higher doses may provoke ischemia with worsening function in the same segment (\u201cbiphasic response\u201d), suggesting viable but jeopardized myocardium. Interpretation depends on image quality and protocol.<\/p>\n<\/li>\n<li>\n<p><strong>Nuclear imaging (SPECT and PET):<\/strong><\/p>\n<\/li>\n<li><strong>Single-photon emission computed tomography (SPECT)<\/strong> perfusion imaging can assess resting perfusion and redistribution patterns with certain tracers, supporting viability in underperfused regions.  <\/li>\n<li>\n<p><strong>Positron emission tomography (PET)<\/strong> with fluorodeoxyglucose (FDG-PET) evaluates glucose metabolism. A pattern of reduced perfusion with preserved metabolism (\u201cperfusion\u2013metabolism mismatch\u201d) supports hibernation.<\/p>\n<\/li>\n<li>\n<p><strong>Cardiac magnetic resonance (CMR):<\/strong><br\/>\n  CMR with late gadolinium enhancement (LGE) characterizes scar. Less LGE (and more preserved wall thickness) generally suggests more viable myocardium. CMR can also assess function and, in many settings, ischemia and perfusion depending on protocol.<\/p>\n<\/li>\n<li>\n<p><strong>Coronary imaging (invasive angiography or coronary CT angiography):<\/strong><br\/>\n  Defining coronary anatomy helps determine whether anatomic targets for revascularization exist. The presence of severe stenoses supports an ischemic mechanism, but stenosis severity does not perfectly predict viability.<\/p>\n<\/li>\n<\/ul>\n\n\n\n<p><strong>Interpretation in practice<\/strong> integrates multiple data points: coronary anatomy, extent and location of dysfunction, scar burden, evidence of contractile reserve, and the patient\u2019s overall clinical status. The threshold for \u201cenough viability to matter\u201d is not universal and varies by clinician and case.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Management overview (General approach)<\/h2>\n\n\n\n<p>Management is not \u201ctreating Myocardial Hibernation\u201d in isolation; it is managing <strong>ischemic LV dysfunction<\/strong> with attention to viability, symptoms, and coronary anatomy. A high-level approach often includes:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>\n<p><strong>Foundational medical therapy for CAD and HF:<\/strong><br\/>\n  Many patients are treated with guideline-directed medical therapy (GDMT) for HF with reduced EF when present, plus therapies targeting ischemic risk (antiplatelet therapy where indicated, lipid-lowering therapy, blood pressure management, diabetes optimization). Specific medication choices and sequencing vary by patient factors and local protocols.<\/p>\n<\/li>\n<li>\n<p><strong>Lifestyle and rehabilitation concepts (supportive care):<\/strong><br\/>\n  Cardiac rehabilitation, exercise guidance, and risk-factor modification may be part of care pathways for appropriate patients, tailored to symptoms and functional capacity. Details vary by program and clinician.<\/p>\n<\/li>\n<li>\n<p><strong>Revascularization consideration (PCI or CABG):<\/strong><br\/>\n  If coronary anatomy is suitable and the clinical context supports it, revascularization may be considered to improve perfusion to viable dysfunctional myocardium. The expected benefits can include improved regional function, changes in symptoms, and possibly prognosis in selected groups; the degree and timing of recovery vary by protocol and patient factors. Decisions are individualized and often multidisciplinary.<\/p>\n<\/li>\n<li>\n<p><strong>Device therapy and advanced HF options (context-dependent):<\/strong><br\/>\n  In patients with persistent LV dysfunction despite medical therapy, clinicians may consider implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy (CRT) depending on rhythm, QRS morphology\/duration, EF, and overall prognosis. Advanced HF therapies may be relevant in refractory cases, independent of viability status.<\/p>\n<\/li>\n<li>\n<p><strong>Ongoing assessment:<\/strong><br\/>\n  Follow-up imaging may be used to reassess EF and remodeling after optimization and\/or revascularization. The choice of modality and timing varies.<\/p>\n<\/li>\n<\/ul>\n\n\n\n<p>Because evidence and patient profiles differ, viability testing may be used to inform management in some cases, while in others coronary anatomy, symptoms, surgical candidacy, and overall risk drive decisions more strongly.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Complications, risks, or limitations<\/h2>\n\n\n\n<p>Myocardial Hibernation as a concept is clinically useful but has important limitations and downstream risks tied to testing and interventions.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Diagnostic limitations:<\/strong><\/li>\n<li>Viability tests can disagree, especially when image quality is limited or when mixed scar and viable tissue coexist.<\/li>\n<li>Chronic remodeling and fibrosis may limit recovery even if myocardium appears viable.<\/li>\n<li>\n<p>Microvascular dysfunction can complicate perfusion assessment.<\/p>\n<\/li>\n<li>\n<p><strong>Stress testing risks (modality-dependent):<\/strong><\/p>\n<\/li>\n<li>Dobutamine stress testing can provoke angina, arrhythmias, or blood pressure changes in susceptible patients.<\/li>\n<li>Nuclear imaging involves radiation exposure.<\/li>\n<li>\n<p>CMR may be limited by implanted devices (depending on device type and local protocols), claustrophobia, or arrhythmias affecting image gating.<\/p>\n<\/li>\n<li>\n<p><strong>Contrast-related considerations:<\/strong><\/p>\n<\/li>\n<li>\n<p>Iodinated contrast (CT\/angiography) and gadolinium-based contrast (CMR) have risks that vary with kidney function and patient factors.<\/p>\n<\/li>\n<li>\n<p><strong>Revascularization risks (context-dependent):<\/strong><\/p>\n<\/li>\n<li>PCI and CABG carry procedural risks such as bleeding, stroke, kidney injury, myocardial infarction, arrhythmias, and infection; the risk profile varies by patient comorbidity and anatomy.<\/li>\n<li>\n<p>Not all patients experience meaningful improvement in LV function after revascularization, even when viability is present.<\/p>\n<\/li>\n<li>\n<p><strong>Clinical decision uncertainty:<\/strong><\/p>\n<\/li>\n<li>The degree to which viability results should change management can be debated, and practice patterns vary by clinician and case.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Prognosis &amp; follow-up considerations<\/h2>\n\n\n\n<p>Prognosis in patients with Myocardial Hibernation depends less on the label itself and more on the broader clinical picture: extent of CAD, LV function, comorbidities, and response to therapy.<\/p>\n\n\n\n<p>Factors that commonly influence outcomes include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>\n<p><strong>Extent of viable vs scarred myocardium:<\/strong><br\/>\n  Greater scar burden generally correlates with less potential for functional recovery and higher arrhythmic risk, though individual risk varies.<\/p>\n<\/li>\n<li>\n<p><strong>Severity and distribution of coronary disease:<\/strong><br\/>\n  Multivessel and left main disease often carry higher risk and may influence revascularization discussions and follow-up intensity.<\/p>\n<\/li>\n<li>\n<p><strong>LV remodeling and baseline EF:<\/strong><br\/>\n  Marked dilation and advanced remodeling can limit the degree of EF improvement even if perfusion is restored.<\/p>\n<\/li>\n<li>\n<p><strong>Success and completeness of revascularization (when performed):<\/strong><br\/>\n  Patency of grafts\/stents, microvascular health, and residual ischemia can affect symptom course and functional recovery.<\/p>\n<\/li>\n<li>\n<p><strong>HF management and comorbidities:<\/strong><br\/>\n  Kidney disease, diabetes, chronic lung disease, anemia, and ongoing tobacco use can worsen prognosis. Adherence to medical therapy and follow-up plans can influence stability, though barriers are common.<\/p>\n<\/li>\n<\/ul>\n\n\n\n<p>Follow-up typically focuses on HF symptoms, functional capacity, volume status, rhythm monitoring when indicated, and periodic reassessment of LV function. The exact schedule and testing strategy vary by protocol and patient factors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Myocardial Hibernation Common questions (FAQ)<\/h2>\n\n\n\n<p><strong>Q: What does Myocardial Hibernation mean in plain language?<\/strong><br\/>\nIt means part of the heart muscle is \u201csleeping,\u201d not dead. The muscle is alive but pumping weakly because it has been living with too little blood flow for a long time. With improved blood supply, some function may return.<\/p>\n\n\n\n<p><strong>Q: Is Myocardial Hibernation the same as a heart attack?<\/strong><br\/>\nNo. A heart attack (myocardial infarction) involves irreversible injury with cell death and scar formation. Myocardial Hibernation refers to viable muscle with reduced function that may improve, depending on how much scar and remodeling are present.<\/p>\n\n\n\n<p><strong>Q: How is Myocardial Hibernation different from myocardial stunning?<\/strong><br\/>\nMyocardial stunning is typically temporary dysfunction after a brief ischemic episode when blood flow has been restored. Myocardial Hibernation is persistent dysfunction associated with chronic hypoperfusion or repeated ischemia. Both describe viable myocardium, but the time course and clinical context differ.<\/p>\n\n\n\n<p><strong>Q: What tests can show whether myocardium is hibernating?<\/strong><br\/>\nCommon tests include dobutamine stress echocardiography (looking for contractile reserve), FDG-PET (metabolism), SPECT perfusion imaging (perfusion patterns), and cardiac MRI with late gadolinium enhancement (scar assessment). Clinicians often interpret these alongside coronary imaging and the overall clinical picture.<\/p>\n\n\n\n<p><strong>Q: Does finding viable myocardium guarantee recovery after revascularization?<\/strong><br\/>\nRecovery is possible but not guaranteed. Improvement depends on factors such as scar burden, duration of dysfunction, LV remodeling, microvascular health, and procedural success. Expectations and timelines vary by clinician and case.<\/p>\n\n\n\n<p><strong>Q: How long can it take for heart function to improve if recovery occurs?<\/strong><br\/>\nSome patients show changes relatively early, while others improve more gradually over weeks to months. Functional recovery can be incomplete even with restored blood flow. Follow-up plans and repeat imaging practices vary by protocol and patient factors.<\/p>\n\n\n\n<p><strong>Q: Is Myocardial Hibernation dangerous by itself?<\/strong><br\/>\nIt is a marker of significant underlying coronary disease and LV dysfunction, which can be associated with HF symptoms and cardiovascular risk. The risk depends on the extent of disease, EF, arrhythmia history, and comorbidities. Clinicians focus on the overall syndrome rather than the term alone.<\/p>\n\n\n\n<p><strong>Q: What are typical \u201cnext steps\u201d after Myocardial Hibernation is suspected?<\/strong><br\/>\nCommon next steps include clarifying coronary anatomy, assessing viability and scar burden, optimizing medical therapy for ischemic heart disease and HF, and discussing whether revascularization is appropriate. The pathway differs across health systems and patient profiles.<\/p>\n\n\n\n<p><strong>Q: Can someone return to normal activities or work with Myocardial Hibernation?<\/strong><br\/>\nFunctional capacity varies widely. Some people have minimal symptoms, while others have significant limitations from HF or angina. Activity recommendations are individualized and often shaped by symptoms, EF, rhythm status, and rehabilitation planning, rather than the viability label alone.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Myocardial Hibernation is a condition in which heart muscle is alive but contracts weakly because it receives chronically reduced blood flow. It is a concept within ischemic heart disease and heart failure (HF) evaluation, not a symptom by itself. It is commonly encountered when assessing left ventricular (LV) dysfunction in coronary artery disease (CAD). It matters because some dysfunction may improve if blood flow is restored.<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-602","post","type-post","status-publish","format-standard","hentry"],"_links":{"self":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/posts\/602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/comments?post=602"}],"version-history":[{"count":0,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/posts\/602\/revisions"}],"wp:attachment":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/media?parent=602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/categories?post=602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/tags?post=602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}